A multicenter phase I/II study of the BCNU implant (gliadelspi ®wafer) for Japanese patients with malignant gliomas

Neurologia Medico-Chirurgica

Volumn 54, Issue 4, 2014, Pages 290-301

  Aoki, Tomokazu ^a   Nishikawa, Ryo ^b   Sugiyama, Kazuhiko ^c   Nonoguchi, Naosuke ^d   Kawabata, Noriyuki ^d   Mishima, Kazuhiko ^b   Adachi, Jun Ichi ^b   Kurisu, Kaoru ^c   Yamasaki, Fumiyuki ^c   Tominaga, Teiji ^e   Kumabe, Toshihiro ^e   Ueki, Keisuke ^f   Higuchi, Fumi ^f   Yamamoto, Tetsuya ^g   Ishikawa, Eiichi ^g   Takeshima, Hideo ^h   Yamashita, Shinji ^h   Arita, Kazunori ⁱ   Hirano, Hirofumi ⁱ   Yamada, Shinobu ^j   Matsutani, Masao ^b   more..

^a NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^b SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d Kitano Hospital   (Japan)

^e TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f DOKKYO MEDICAL UNIVERSITY   (Japan)

^g UNIVERSITY OF TSUKUBA   (Japan)

^h UNIVERSITY OF MIYAZAKI HOSPITAL   (Japan)

ⁱ KAGOSHIMA UNIVERSITY   (Japan)

^j Nobelpharma Co Ltd   (Japan)

more..

Author keywords

BCNU implant; Gliadel wafer; Malignant gliomas; Pharmacokinetic; Phase I II study

Indexed keywords

BETA INTERFERON; BEVACIZUMAB; CARMUSTINE; GADOLINIUM; PLACEBO; TEMOZOLOMIDE; ALKYLATING AGENT; CARMUSTINE, POLIFERPROSAN 20 DRUG COMBINATION; DECANOIC ACID DERIVATIVE; DRUG IMPLANT; POLYESTER;

ADULT; APPLICATION SITE REACTION; ARTICLE; BREAST DISEASE; CARMUSTINE IMPLANT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG IMPLANT; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; GLIOBLASTOMA; HUMAN; MALE; MENTAL DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SKIN DISEASE; TUMOR GROWTH; TUMOR VOLUME; WOUND COMPLICATION; AGED; BRAIN NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GASTROINTESTINAL DISEASES; GLIOMA; JAPAN; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; NERVOUS SYSTEM DISEASES;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CARMUSTINE; COMBINED MODALITY THERAPY; DECANOIC ACIDS; DISEASE-FREE SURVIVAL; DRUG IMPLANTS; FEMALE; GASTROINTESTINAL DISEASES; GLIOMA; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; NERVOUS SYSTEM DISEASES; POLYESTERS; PROSPECTIVE STUDIES;

EID: 84927671658     PISSN: 04708105     EISSN: 13498029     Source Type: Journal    
DOI: 10.2176/nmc.oa2013-0112     Document Type: Article

References (14)

1. Committee of Brain Tumor Registry of Japan: Report of brain tumor registry of Japan (1984-2000), ed 12. Neurol Med Chir (Tokyo) 49(Suppl): S1-S96, 2009
2. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345: 1008-1012, 1995
3. Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L, Heiskanen O, Unsgaard G, Kuurne T: Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 41: 44-48; discussion 48-49, 1997
4. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, Whittle IR, Jääskeläinen J, Ram Z: A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5: 79-88, 2003
5. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology-v.1, 2013
6. National Cancer Institute Cancer Information Physician Data Query (May, 2012) Neurol Med Chir (Tokyo) 54, April, 2014
7. National Institute for Health and Clinical Excellence. (June, 2007)
8. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005
9. Affronti ML, Heery CR, Herndon JE, Rich JN, Reardon DA, Desjardins A, Vredenburgh JJ, Friedman AH, Bigner DD, Friedman HS: Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer 115: 3501-3511, 2009
10. Bock HC, Puchner MJ, Lohmann F, Schütze M, Koll S, Ketter R, Buchalla R, Rainov N, Kantelhardt SR, Rohde V, Giese A: First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. Neurosurg Rev 33: 441-449, 2010
11. Larocca RV, Vitaz TW, Morassutti DJ, Doyle MJ, Glisson SD, Hargis JB, Goldsmith GH, Cervera A, Stribinskiene L, New P: A phase II study of radiation with concomitant and then sequential temozolomide (TMZ) in patients with newly diagnosed supratentorial high-grade malignant glioma who have undergone surgery with carmustine (BCNU) wafer insertion. Neuro Oncol 8: 391-500, 2006
12. McGirt MJ, Than KD, Weingart JD, Chaichana KL, Attenello FJ, Olivi A, Laterra J, Kleinberg LR, Grossman SA, Brem H, Quiñones-Hinojosa A: Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 110: 583-588, 2009
13. Pan E, Mitchell SB, Tsai JS: A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. J Neurooncol 88: 353-357, 2008
14. Jones RB, Matthes S, Shpall EJ, Fisher JH, Stemmer SM, Dufton C, Stephens JK, Bearman SI: Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine. J Natl Cancer Inst 85: 640-647, 1993